Genmab (Otc) ((GMAB)), Biontech Se Sponsored Adr ((BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Genmab and BioNTech SE are conducting a trial titled ‘First-In-Human, Open-Label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects With Malignant Solid Tumors.’ The study aims to assess the safety and preliminary efficacy of the antibody GEN1055, both alone and in combination with pembrolizumab, with or without chemotherapy, in treating malignant solid tumors. This trial is significant as it explores new treatment avenues for cancer patients.
The interventions being tested include GEN1055, a biological agent administered intravenously, pembrolizumab, another biological agent, and standard chemotherapy. These treatments aim to evaluate their combined effectiveness against cancer.
The study design is interventional with a sequential intervention model and no masking, focusing primarily on treatment. It consists of two parts: dose escalation to determine safe dosage and expansion to evaluate the treatment’s effectiveness.
The trial began on May 14, 2024, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on July 7, 2025, indicating the ongoing nature of the study.
This clinical study update could potentially impact Genmab and BioNTech’s stock performance positively, as successful results may enhance investor confidence and market position. Given the competitive landscape in cancer treatment, advancements in this trial could position these companies favorably against competitors.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.